Viatris Inc. (VTRS) News
Track canonical SquawkNews coverage tagged to VTRS, Viatris Inc.. This hub brings together deduplicated headlines about united states, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 14 indexed stories across 10 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
VTRS - Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome
VTRS - Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome
NEWS | Sep 16, 2026, 10:59 AM UTC
L
Viatris initiated at Outperform, $20 price target by Leerink
Leerink Partners initiated coverage on Viatris with an Outperform rating and a $20.00/share price target.
EQUITY | Sep 09, 2026, 03:53 PM UTC
L
Viatris price target lifted to $20 by Argus Research
Argus Research raised its price target on Viatris to $20.00 per share from $15.00, according to ratings actions cited by Benzinga (via TradingView News).
EQUITY | Sep 08, 2026, 01:00 PM UTC
M
Roivant drug meets mid-stage goals; ROIV shares jump premarket
Roivant (ROIV) said its experimental drug met the main goals of a mid-stage study in patients with high blood pressure associated with a type of lung disease, sending shares up about 20% in premarket trading.
EQUITY | Sep 08, 2026, 10:59 AM UTC
H
Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook
Harrow Inc. (NASDAQ: HROW ) on Thursday agreed to acquire Tyrvaya (varenicline solution) nasal spray 0.03 mg from Viatris Inc. (NASDAQ: VTRS ). Viatris To Sell Tyrvaya To Harrow In Up To $100 Million Deal Tyrvaya is a ch
EARNINGS | Aug 06, 2026, 05:56 PM UTC
H
VTRS Beats Revenue Estimates
VTRS reports $3.8B revenue, beating estimates
EARNINGS | Aug 06, 2026, 11:05 AM UTC
H
Viatris Raises FY2026 Adj EPS Guidance from $2.33-$2.47 to $2.45-$2.49 vs $2.44 Est; Raises FY2026 Sales Guidance from $14.450B-$14.950B to
Viatris (NASDAQ: VTRS ) raises FY2026 Adj EPS guidance from $2.33-$2.47 to $2.45-$2.49 vs $2.44 analyst estimate. Raises FY2026 sales outlook from $14.450 billion-$14.950 billion to $14.550 billion-$14.950 billion vs $14
EARNINGS | Aug 06, 2026, 11:00 AM UTC
L
VTRS VTRS - Viatris Reports Second-Quarter 2026 Financial Results
VTRS VTRS - Viatris Reports Second-Quarter 2026 Financial Results
EQUITY | Aug 06, 2026, 10:59 AM UTC
L
Viatris Announces Quarterly Dividend
Viatris declares quarterly dividend
EQUITY | Aug 04, 2026, 11:00 AM UTC
L
VTRS VTRS - Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch
VTRS VTRS - Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch
REGULATION | Jul 29, 2026, 10:59 AM UTC
L
AMRX TEVA favored names in generics and neutral on VTRS in Q2 preview @ GSCO
AMRX TEVA favored names in generics and neutral on VTRS in Q2 preview @ GSCO
EQUITY | Jul 22, 2026, 12:51 PM UTC
L
ELVT SNY OTSKY MNKD OTLK VTRS Here are the key confirmed or reported upcoming PDUFA (Prescription Drug User Fee Act) target action dates for
ELVT SNY OTSKY MNKD OTLK VTRS Here are the key confirmed or reported upcoming PDUFA (Prescription Drug User Fee Act) target action dates for remainder of month: --ELVT expected around 7/23 – Drug rivoceranib + camrelizum
EQUITY | Jul 20, 2026, 05:31 PM UTC
L
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. re
RATES | Jul 14, 2026, 11:30 AM UTC
H
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Analysts' ratings for high-yielding health care stocks: Viatris, Medtronic, and GSK.
EQUITY | Jun 29, 2026, 11:46 AM UTC